贝伐珠单抗联合化疗治疗晚期胃癌的疗效观察

Efficacy observation of bevacizumab combined with chemotherapy in the treatment of advanced gastric cancer

目的 分析晚期胃癌实施化疗联合贝伐珠单抗治疗的效果。方法 64例晚期胃癌患者,基于双盲法分组规则分为对照组与观察组,每组32例。对照组行临床常规的化疗治疗,观察组基于对照组联合使用贝伐珠单抗治疗。比较两组疗效、生存质量评分、血清肿瘤标志物水平。结果 观察组治疗总有效率71.87%高于对照组的46.87%,差异有统计学意义(P<0.05)。观察组生存质量评分(70.34±2.51)分高于对照组的(52.37±2.35)分,差异有统计学意义(P<0.05)。治疗后,观察组的血清配癌抗原(21.34±4.51)ng/ml、糖类抗原199(206.28±38.72)ng/ml均低于对照组的(28.65±5.85)、(233.07±36.41)ng/ml,差异有统计学意义(P<0.05)。结论 对晚期胃癌患者实施常规化疗的同时联合贝伐珠单抗治疗,能提高治疗效果,进一步改善患者的生活质量,降低肿瘤标志物水平,值得临床参考。

Objective To analyze the effect of bevacizumab combined with chemotherapy in the treatment of advanced gastric cancer.Methods A total of 64 patients with advanced gastric cancer were divided into control group and observation group based on double-blind method,with 32 cases in each group.The control group was treated with conventional clinical chemotherapy,and the observation group was treated with bevacizumab based on the control group.The efficacy,quality of life score,and serum tumor marker levels were compared between the two groups.Results The total effective rate of treatment 71.87%in the observation group was higher than 46.87%in the control group,and the difference was statistically significant(P<0.05).The quality of life score(70.34±2.51)points of the observation group was higher than(52.37±2.35)points of the control group,and the difference was statistically significant(P<0.05).After treatment,the serum carcinoembryonic antigen(21.34±4.51)ng/ml and carbohydrate antigen 199(206.28±38.72)ng/ml of the observation group were lower than(28.65±5.85)and(233.07±36.41)ng/ml of the control group,and the difference was statistically significant(P<0.05).Conclusion Conventional chemotherapy combined with bevacizumab for patients with advanced gastric cancer can improve the quality of life and lower the serum tumor marker levels of patients,which is worthy of clinical reference.